Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 389

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 389
---
     |        766 |   |     |         76 |   |
| Additions                             |     |          – |   |     |          – |   |     |        720 |   |
| Transfer                              |     |          – |   |     |          – |   |     |         77 |   |
| Effect of modification to lease terms |     |          – |   |     |          – |   |     |        (24 | ) |
| Interest expenses                     |     |         28 |   |     |         36 |   |     |         29 |   |
| Lease payments                        |     |       (188 | ) |     |       (178 | ) |     |       (112 | ) |
| At 31 December                        |     |        464 |   |     |        624 |   |     |        766 |   |

The right of use assets is disclosed in note 9.

In
April 2021 the Group signed an agreement to lease new premises in Cardiff, Wales, to house its corporate offices and laboratories. The
agreement to lease allowed the Group to carry out the Cat A works and fit out prior to completion of the lease and its occupation in August
2021. The lease agreed was for a 5 year period with no break clause. The lease was recognised as a right of use asset in 2021. The recognition
in 2021 of the right of use asset and corresponding lease liability were a non cash investing and financing transaction.

In
May 2021 the Group provided notice to terminate its property lease on its historical building in Cardiff. The lease required 6 months’
notice.

Low value leases expensed in year:

| Low value leases expensed in year |     |            |     |            |     |            |
|                                   |     | 2023 £’000 |     | 2022 £’000 |     | 2021 £’000 |
| Low value leases expensed         |     |          2 |     |          3 |     |          2 |
|                                   |     |          2 |     |          3 |     |          2 |

Total
cash outflow for leases in 2023 was £190k (2022: £181k; 2021: £114k)

| F-49 |

| 11 | Intangible assets |

| Schedule of intangible assets               |     |                                           |